Literature DB >> 2436011

Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans.

M Boivin, A R Zinsmeister, V L Go, E P DiMagno.   

Abstract

In previous studies we found that in healthy subjects, 5 and 10 g of a partially purified amylase inhibitor delayed and decreased starch digestion and reduced postprandial plasma glucose after a starch meal but produced diarrhea in two of six and four of six subjects, respectively. Thus, we wondered whether lower doses of the inhibitor, when given with a meal that contained protein and fat as well as carbohydrate, would have the same effect on carbohydrate tolerance without causing diarrhea. Eight healthy subjects were randomized to receive 2.0 or 2.9 g of the inhibitor with a 650-calorie meal that contained carbohydrate, fat, and protein. In comparison with a placebo, ingestion of 2.9 g, but not 2.0 g, of the inhibitor significantly reduced postprandial increases in plasma glucose (P less than 0.05), C peptide (P less than 0.03), and gastric inhibitory polypeptide (P less than 0.008). Similarly, 2.9 g of the inhibitor in comparison with 2.0 g was associated with more carbohydrate malabsorption and more breath hydrogen excretion. Because the carbohydrate malabsorption observed with the 2.9-g dose was similar to that with the previously tested 5- and 10-g doses of the inhibitor but diarrhea was less frequent, impurities in the partially purified preparation may, in part, have been responsible for these adverse effects. We conclude that 2.9 g of the amylase inhibitor given with a meal that contains a mixture of nutrients is effective in increasing carbohydrate tolerance without causing diarrhea. Therefore, this dose is appropriate for use in studies to determine whether the inhibitor has a beneficial effect in patients with diabetes mellitus or obesity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2436011     DOI: 10.1016/s0025-6196(12)61900-4

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Carbohydrate digestion and release of pancreatic polypeptide in health and diabetes mellitus.

Authors:  P Layer; V L Go; E P DiMagno
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

2.  Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro.

Authors:  M Hiele; Y Ghoos; P Rutgeerts; G Vantrappen
Journal:  Dig Dis Sci       Date:  1992-07       Impact factor: 3.199

3.  Antioxidant rich grape pomace extract suppresses postprandial hyperglycemia in diabetic mice by specifically inhibiting alpha-glucosidase.

Authors:  Shelly Hogan; Lei Zhang; Jianrong Li; Shi Sun; Corene Canning; Kequan Zhou
Journal:  Nutr Metab (Lond)       Date:  2010-08-27       Impact factor: 4.169

Review 4.  A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control.

Authors:  Marilyn L Barrett; Jay K Udani
Journal:  Nutr J       Date:  2011-03-17       Impact factor: 3.271

5.  Potential efficacy of preparations derived from Phaseolus vulgaris in the control of appetite, energy intake, and carbohydrate metabolism.

Authors:  Mauro Am Carai; Noemi Fantini; Barbara Loi; Giancarlo Colombo; Antonella Riva; Paolo Morazzoni
Journal:  Diabetes Metab Syndr Obes       Date:  2009-09-07       Impact factor: 3.168

Review 6.  Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.

Authors:  Stefania Peddio; Alessandra Padiglia; Faustina B Cannea; Roberto Crnjar; Wissam Zam; Javad Sharifi-Rad; Antonio Rescigno; Paolo Zucca
Journal:  Phytother Res       Date:  2022-04-29       Impact factor: 6.388

7.  A Phaseolus vulgaris Extract Reduces Cue-Induced Reinstatement of Chocolate Seeking in Rats.

Authors:  Irene Lorrai; Valentina Piga; Mauro A M Carai; Antonella Riva; Paolo Morazzoni; Gian Luigi Gessa; Giancarlo Colombo; Paola Maccioni
Journal:  Front Pharmacol       Date:  2016-04-26       Impact factor: 5.810

8.  Potent Human α-Amylase Inhibition by the β-Defensin-like Protein Helianthamide.

Authors:  Christina Tysoe; Leslie K Williams; Robert Keyzers; Nham T Nguyen; Chris Tarling; Jacqueline Wicki; Ethan D Goddard-Borger; Adeleke H Aguda; Suzanne Perry; Leonard J Foster; Raymond J Andersen; Gary D Brayer; Stephen G Withers
Journal:  ACS Cent Sci       Date:  2016-02-26       Impact factor: 14.553

Review 9.  Microbial drug discovery: 80 years of progress.

Authors:  Arnold L Demain; Sergio Sanchez
Journal:  J Antibiot (Tokyo)       Date:  2009-01-09       Impact factor: 2.649

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.